Trial Profile

A Phase 1 clinical trial to determine clinical outcomes KIN-7136 combined with exarafenib in patients with NSCLC that have been previously treated with a RAF inhibitor and patients with NRAS mutant melanoma

Status: Suspended

Phase of Trial: Phase I

Latest Information Update: 22 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Exarafenib (Primary) ; KIN-7136 (Primary)
Indications Brain metastases; Malignant melanoma; Non-small cell lung cancer; Solid tumours
Focus Adverse reactions
Sponsors Kinnate Biopharma

18 Sep 2023 Status changed from planning to suspended.
18 Sep 2023 According to Kinnate Biopharma Inc media release, the company has paused development of KIN-7136 as part of the reprioritization plan based on a strategic review of its business. The Company will not initiate a clinical trial for KIN-7136 at this time.
24 Apr 2023 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com